Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.75    -0.375 (-2.65%)
Bid:
13.50
Ask:
14.00
Spread: 0.50 (3.704%)
Market Cap: £61.76m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Framework Distribution Agreement for India

26 Sep 2019 07:00

RNS Number : 7058N
Creo Medical Group PLC
26 September 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

Framework Distribution Agreement for India

Indian doctors and nurses trained on Speedboat following signing

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it has entered into a Distribution Partner Framework Agreement (the "Agreement") with MEDITEK SYSTEMS ("Meditek"), to provide clinical training and market seeding across the Indian market for Creo's CROMA Advance Energy platform and suite of products, including the Speedboat device, ahead of their official launch.

 

Meditek will collaborate with Creo to advance the roll out of Creo's Clinical Education Programme across the Indian market, training key clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes. Creo's Clinical Education Programme ensures that distributor trainers, having been carefully mentored, can then deliver in-country training for clinicians at a consistently high standard.

 

In addition, doctors and nurses from six key healthcare institutions in India have already completed training as part of Creo's Clinical Education Programme ahead of the mentoring phase of the programme with initial cases taking place in India over the coming weeks.

 

Meditek will continue to operate the Clinical Education Programme in India and will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed. The Agreement requires Meditek to purchase a minimum quantity of CROMA advance energy platforms and Speedboat products during the initial period.

 

About Speedboat

The Company's Speedboat device is the first in a range of GI devices to be cleared for use with the CROMA advanced energy platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. Speedboat enables the removal of lesions from the colon using an endoscope, whilst patients are under sedation and with regular procedure times of under one hour. Patients can be discharged on the same day for routine follow-up and monitoring, without recourse to lengthy laparoscopic surgery which requires hospitalised recovery over a number of days.

 

Craig Gulliford, Chief Executive Officer of Creo, commented: "We are delighted to begin working with Meditek to introduce our innovative product range to the Indian market, one of the fastest growing healthcare markets in the world which is also rapidly gaining recognition for pioneering clinical practice. We will continue to widen the reach of our Clinical Education Programme to ensure the highest standards are applied to the safe and effective adoption of our portfolio of products for surgical endoscopy."

 

Creo Medical Group plc

investors.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Cameron MacRitchie

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7515 909 238

 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 

About Meditek Systems

Meditek Systems was formed in 1997 and is headquartered in New Delhi, India. Meditek aims to provide the latest available products to the medical industry in India and is one of India's fastest growing marketing & distribution houses dealing with several Multinational corporations which are industry experts and leaders in device manufacturing for Cardiology, Gastroenterology, Respiratory and Radiology. https://www.mediteksystems.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLAMMTMBJTTJL
Date   Source Headline
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan
15th Jan 20257:00 amRNSFirst robotic-guided lung ablation cases commence
16th Dec 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.